Intracytoplasmic detection of TCL1-but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis

Cytometry Part A

Volumn 81 A, Issue 8, 2012, Pages 718-724

  Angelot Delettre, Fanny ^a,b,c   Biichle, Sabeha ^b,c   Ferrand, Christophe ^a,b,c   Seilles, Estelle ^a,b,c   Gaugler, Béatrice ^b,c,d   Harrivel, Veronique ^e   Rosenthal Allieri, Maria Alessandra ^f   Deconinck, Eric ^b,c,d   Saas, Philippe ^a,b,c,d   Garnache Ottou, Francine ^a,b,c,d  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Acute leukemia; Blastic plasmacytoid dendritic cell neoplasm; Diagnosis; Flow cytometry; ILT7; Plasmacytoid dendritic cell leukemia; TCL1

Indexed keywords

IMMUNOGLOBULIN RECEPTOR; LILRA4 PROTEIN, HUMAN; ONCOPROTEIN; TCL1A PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BLOOD; CYTOPLASM; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKEMIA; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADOLESCENT; AGED; AGED, 80 AND OVER; BLAST CRISIS; CYTOPLASM; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 84864018648     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22072     Document Type: Article

References (25)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
2. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Bene MC. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002; 99: 1556-1563.
3. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, Jaffe ES. Blastic plasmacytoid dendritic cell neoplasm in children: Diagnostic features and clinical implications. Haematologica 2010; 95: 1873-1879.
4. Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, Konrad Muller-Hermelink H, Wilhelm M. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003; 32: 637-646.
5. Marafioti T, Paterson JC, Ballabio E, Reichard KK, Tedoldi S, Hollowood K, Dictor M, Hansmann ML, Pileri SA, Dyer MJ, Sozzani S, Dikic I, Shaw AS, Petrella T, Stein H, Isaacson PG, Facchetti F, Mason DY. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008; 111: 3778-3792.
6. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007; 109: 1720-1727.
7. Jardin F, Callanan M, Penther D, Ruminy P, Troussard X, Kerckaert JP, Figeac M, Parmentier F, Rainville V, Vaida I, Bertrand P, Duval AB, Picquenot JM, Chaperot L, Marolleau JP, Plumas J, Tilly H, Bastard C. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia 2009; 23: 698-707.
8. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: Towards a well defined entity? Br J Haematol 2007; 136: 539-548.
9. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, Metze D, Fink-Puches R, Wiesner T, Cerroni L. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34: 75-87.
10. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadie M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 2009; 145: 624-636.
11. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 2005; 105: 1256-1264. Epub 2004 Sep 1223.
12. Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadie M, Machet L, Casasnovas O, Vergier B, Teitell MA. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 2004; 122: 307-313.
13. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukemia. Oncogene 2001; 20: 5638-5643.
14. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003; 101: 5007-5009. Epub 2003 Feb 5006.
15. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D, Scala E, Baroni CD, Stoppacciaro A, Croce CM, Russo G. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000; 60: 2095-2100.
16. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB, Zenke M. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene 2004; 331: 159-164.
17. Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, Locksley R, Holmberg D, Zweier C, den Hollander NS, Kant SG, Holter W, Rauch A, Zhuang Y, Reizis B. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 2008; 135: 37-48.
18. Cao W, Liu YJ. Opn: Key regulator of pDC interferon production. Nat Immunol 2006; 7: 441-443.
19. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
20. Garand R, Robillard N. Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: Practical recommendations and classifications. Hematol Cell Ther 1996; 38: 471-486.
21. Cao W, Bover L. Signaling and ligand interaction of ILT7: Receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev 2010; 234: 163-176.
22. Martin-Martin L, Almeida J, Hernandez-Campo PM, Sanchez ML, Lecrevisse Q, Orfao A. Immunophenotypical, morphologic, and functional characterization of maturation-associated plasmacytoid dendritic cell subsets in normal adult human bone marrow. Transfusion 2009; 49: 1692-1708.
23. Cao W, Rosen DB, Ito T, Bover L, Bao M, Watanabe G, Yao Z, Zhang L, Lanier LL, Liu YJ. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 2006; 203: 1399-1405.
24. Dargent JL, Delannoy A, Pieron P, Husson B, Debecker C, Petrella T. Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: A rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. J Cutan Pathol 2011; 38: 893-898.
25. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590-11593.